Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 153 participants.

Also called NCT02220907

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 153 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02220907
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02220907. Allocation not applicable; no masking; primary purpose treatment. Start 2014-08 (registry gives no type); primary completion 2016-02 (actual). Results posted on 2018-08-16.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Teneligliptin/Canagliflozin
Lead sponsor
Tanabe Pharma Corporation (class: industry)

Record details

Record id
cardio:ct-nct02220907
Content hash
d43f952347821b4f449e5da60e826ec0b70c22a1cadb29cd5c1e1d7c1ac6de95